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Abstract
Recent immune correlates analysis from the RV144 vaccine trial has renewed interest in the role of non-neutralizing
antibodies in mediating protection from infection. While neutralizing antibodies have proven difficult to induce through
vaccination, extra-neutralizing antibodies, such as those that mediate antibody-dependent cellular cytotoxicity (ADCC), are
associated with long-term control of infection. However, while several non-neutralizing monoclonal antibodies have been
tested for their protective efficacy in vivo, no studies to date have tested the protective activity of naturally produced
polyclonal antibodies from individuals harboring potent ADCC activity. Because ADCC-inducing antibodies are highly
enriched in elite controllers (EC), we passively transferred highly functional non-neutralizing polyclonal antibodies, purified
from an EC, to assess the potential impact of polyclonal non-neutralizing antibodies on a stringent SHIV-SF162P3 challenge
in rhesus monkeys. Passive transfer of a low-dose of ADCC inducing antibodies did not protect from infection following
SHIV-SF162P3 challenge. Passively administered antibody titers and gp120-specific, but not gp41-specific, ADCC and
antibody induced phagocytosis (ADCP) were detected in the majority of the monkeys, but did not correlate with post
infection viral control. Thus these data raise the possibility that gp120-specific ADCC activity alone may not be sufficient to
control viremia post infection but that other specificities or Fc-effector profiles, alone or in combination, may have an
impact on viral control and should be tested in future passive transfer experiments.
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Introduction
While a large number of novel, broadly neutralizing antibodies
have been described recently, the induction of such antibodies
through vaccination in humans has proven difficult [1]. Neutral-
izing antibodies develop in approximately one third of infected
patients, only after two to three years of infection [2–4]. However,
the mechanism by which these individuals are able to induce
broad humoral immunity, though often after viral escape, is not
understood.
Yet beyond neutralization, antibodies possess a large variety of
additional extra-neutralizing properties that allow them to control
and eliminate infections, including antibody-dependent cellular
cytotoxicity (ADCC), antibody-dependent cellular phagocytosis
(ADCP) of immune complexes, antibody-dependent cellular viral
inhibition (ADCVI) [5] and complement activation [6,7]. Anti-
bodies mediate these functions via the recruitment of the innate
immune system through Fc/Fc-c receptor (FccR) interactions or
the recruitment of complement. Moreover the role of these extra-
neutralizing functions in the control of HIV have been most
clearly illustrated using a variant of b12 with abrogated capacity to
interact with Fc receptors that reduced the protective efficacy of
passively transferred b12 in rhesus macaques [8].
Non-neutralizing antibodies with innate immune–stimulating
activities (e.g., ADCC-inducing antibodies) have been shown to
play a crucial role in the clearance of several viral infections [9–
11]. In HIV [12–16], antibodies with innate immune–recruiting
activity have been detected in acutely infected individuals [12] and
subjects who spontaneously control HIV infection in the absence
of therapy [12,17]. Furthermore, strong ADCVI responses are
associated with slower disease progression in long-term non-
progressors [12,13,18–20], suggesting that antibodies with specific
innate immune–activating properties may contribute to viral
containment in vivo. Additionally, vaccine-elicited, non-neutraliz-
ing-ADCC-inducing antibodies [21–24] or the passive transfer of
ADCC-inducing-non-neutralizing antibodies [25] have been
repeatedly shown to contribute to antiviral control post-infection,
further highlighting the importance of non-neutralizing antibody
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immune correlates analysis of the RV144 vaccine trial demon-
strated that ADCC activity, in the absence of vaccine-elicited IgA
responses, was associated with a reduced risk of infection among
vaccinees, supporting a role for vaccine-elicited non-neutralizing
antibodies in protection for the first time [26].
Importantly, unlike neutralizing antibodies that target a limited
network of neutralizing epitopes on the viral envelope, non-
neutralizing antibodies may require the synergistic targeting of a
much larger spectrum of epitopes to form an immune complex.
Together, this targeting provides the avidity necessary to trigger
the relatively low-affinity innate immune receptors, thereby
allowing for rapid target cell elimination. Therefore, while non-
neutralizing monoclonal antibodies, or combinations of several
monoclonal antibodies, have afforded only limited protection from
infection, it is plausible that a polyclonal pool of highly functional
antibodies that target a broad range of epitopes may increase the
ability of non-neutralizing antibodies to prevent or control HIV
infection. Here we assessed whether polyclonal antibodies from a
patient with robust non-neutralizing activity could provide
protection from infection or mediate virological control following
SHIV-SF162P3 challenge in rhesus macaques. Overall, passive
transfer of a low-dose of a polyclonal pool of ADCC-inducing non-
neutralizing antibodies did not provide sterilizing protection
following intrarectal challenge with SHIV-SF162P3. Ancillary
analyzes demonstrate the selective persistence of IgG1 Abs and
functional responses against gp120, but not gp41 after transfer in
the blood, but not at the mucosa, potentially accounting for lack of
protection from challenge.
Materials and Methods
Patients
Samples from a total of 15 elite controllers were included in this
study, and IgG from one elite controller with robust innate–
recruiting activity in the absence of neutralization was selected for
passive transfer. In addition, a pool of IgG derived from five
uninfected healthy individuals was used as a control. The MGH
Institutional Review Board approved the study, and each subject
provided written informed consent.
Antibody purification
For functional studies, human antibodies were isolated from
100 mL of plasma. For passive transfer, IgG isolation was
performed on 100 mL of plasma from a single elite controller or
100 mL of pooled plasma from five healthy controls using protein
A followed by protein A/G Sepharose columns. Rhesus macaque
antibodies were isolated from plasma using a Melon Gel IgG
Purification Kit, as recommended by the manufacturer (Thermo
Scientific). No differences were observed in antibody subclass
distribution or function following melon gel or protein A/G
purification. IgGs were also tested for their ability to interfere or
block SHIV/HIV infection in vitro, and no effect was observed.
Animals
Eleven Mamu-A*01-, B*17-, and B*08-negative adult Indian-
origin rhesus monkeys were housed at the New England Primate
Research Center, as recommended by the Guide for the Care and
Use of Laboratory Animals. All studies were approved by the
Institutional Animal Care and Use Committee (IACUC) of
Harvard Medical School. Standard nutritious monkey diets were
provided to each animal three times a day by skilled veterinary
staff, in accordance with NEPRC standard operating procedures
for veterinary care. No food or water deprivation occurred during
the study. Animals were housed one per cage because socialized
housing of animals under these circumstances increases the risk of
transmission of the infectious agents, which could invalidate the
study. Sources of enrichment included manipulation devices,
foraging opportunities, food items, structural and environmental
enhancements, and positive human interaction. Enrichment
devices were rotated on a weekly basis and included toys, mirrors,
radios, TV/VCRs, foraging boards, and a variety of complex
foraging devices. To alleviate suffering, animals were fasted for
12 hours prior to any procedure and were given anesthesia,
Ketamine HCL (10–20 mg/kg IM) for blood draws and colorectal
biopsies. Following sample collections, the animals were moni-
tored by the veterinary staff until recovered. Animals were
humanely euthanized 3 months post antibody infusion by
barbiturate overdose following anesthesia, in accordance with
IACUC and HVMA guidelines.
Challenge experiment
Five rhesus macaques received intravenous transfer (IV) of
50 mg/kg of the antibodies isolated from the elite controller, five
rhesus macaques received IV transfer of 50 mg/kg of antibodies
isolated from the healthy controls and one rhesus macaque
received 25 mg/kg of the neutralizing monoclonal antibody b12
one day prior to intrarectal challenge with SHIV-SF162P3. SHIV-
SF162P3 was generated in rhesus PBMC and was administered
intrarectally at an intermediate dose (7.3 log RNA copies/mL or
340 TCID50) designed to infect the majority but not all of the
animals.
Sample collection
Plasma samples were collected on days 1, 3, 7, 14, 21, 28, 56
and 84 post-challenge and stored at 280uC. The plasma viral load
was determined using the commercially available branched DNA
(bDNA) kit (Siemens).
ADCVI assay
Peripheral blood mononuclear cells (PBMCs) were prepared
from the whole blood of healthy control rhesus macaques using
density gradient centrifugation and Ficoll-paque PLUS (GE
Healthcare). CD4
+ T cells were obtained using a CD8 Depletion
Kit (Stem Cell Technology) and cultured (5610
6/mL) for 3 days
in RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 100 mg/mL penicillin, 100 U/mL streptomycin,
10 mM HEPES, 50 U/mL IL-2 and 5 mg/mL PHA to activate
the cells. On day 3, NK cells were isolated from the same donor
rhesus macaque using a CD3 Depletion Kit (Stem Cell
Technology). On the same day, the activated CD4
+ T cells were
infected with SHIV-SF162P3 at an MOI of 0.01 for 4 hours at
37uC. CD4
+ T cells and NK cells were plated in 96-well round-
bottom plates at an effector:target ratio of 10:1 in the presence or
absence of 50 mg/mL of antibody from the elite controller or the
negative donor. Infected CD4
+ T cells incubated with 50 mg/mL
of antibody in the absence of effector cells served as a control to
measure the capacity of each HIV-specific antibody to neutralize
the virus and was complementary to the TZMBL assay, also aimed
at measuring antibody neutralizing activity [27]. After 4 days of
culture, the supernatant was collected, and viral replication was
quantified using a p27 ELISA (Advanced Bioscience Laborato-
ries). The inhibition of viral replication was calculated as follows:
% Inhibition = (100-[100*{p27 concentration in wells containing
effectors, targets and antibody}/{p27 concentration in wells
containing targets and antibody}]).
In addition, we measured the ability of 50 ug/mL of human
plasma purified antibodies to recruit human NK cells and suppress
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Briefly, peripheral blood mononuclear cells (PBMC) were
prepared from the whole blood of HIV-negative donors using
Ficoll Hypaque density gradient centrifugation. CD4s were
obtained following 3 days of PBMCs culture at 5610
6/mL in
RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 ug/mL penicillin, 100 U/mL streptomycin, Hepes
and 50 U/mL of IL-2 in the presence of 0.3 ug/mL of anti-CD3/
8 antibodies. On day 3, autologous NK cells were isolated from
the same donor using a Rosette Sep enrichment kit (Stem cell). On
the same day, CD4 cells were infected with JRCSF or SF162 at a
multiplicity of infection (MOI) of 0.01 for 4 hours at 37 degrees.
Both CD4s and NK cells were washed and plated in 96 well round
bottomed plates at an effector:target ratio of 10:1 in the presence
or absence of 50 ug/mL of antibody from Elite Controllers or
HIV negative individuals. Infected CD4 cells incubated with
50 ug/mL of antibody in the absence of effector cells served as a
control to measure the capacity of each antibody to neutralize the
virus. After 4 days of culture, the supernatant was collected and
the viral replication was quantified by p24 ELISA (Perkin Elmer).
Inhibition of viral replication was calculated as follows: %
Inhibition = [100-((p24 concentration in wells containing
effector-target-antibody)/(p24 concentration in wells containing
effector-antibody)*100)]. NK and CD4 T cells were prepared from
a minimum of two different healthy individuals to perform the
ADCVI assay.
HIV-specific antibody titer quantification
ELISA plates (Nunc) were coated overnight at 4uC with 80 mL
of PBS containing 250 ng/mL recombinant YU-2 gp120, SF162
gp120 or SHIVgp140SF162p3 (Immune technology). The wells
were washed six times with PBS containing 0.05% Tween 20,
blocked with 100 mL of PBS containing 5% BSA at room
temperature for 2 hours and washed again. Serial dilutions of
antibodies starting at 1 mg/mL in 45 mL were then added to each
well, and the plates were incubated at room temperature for
2 hours. A pool of immunoglobulins from HIV-positive individ-
uals (AIDS Reagent Program, Division of AIDS, NIAID, NIH;
Catalog #3957, HIV-IG from NABI and NHLBI) was used as a
positive control. After six washes, 100 mL of horseradish perox-
idase–conjugated anti-human IgG (1:500, diluted in PBS; BD
Pharmingen) was added to each well, and the plate was incubated
for 1 hour at room temperature, washed and developed by the
addition of 50 mL of O-phenyl-enediamine diluted in 11 mL PBS.
The reaction was stopped, and the optical densities at 492 and
605 nm were read on a Tecan ELISA reader. The data were
analyzed in Prism, and the EC50 was calculated for each sample
as follows: Y=Min+[(Max2Min)/(1+10
LogEC50-X)] where Y is the
observed value, Min is the lowest observed value, Max is the
highest observed value, X is the value when the response is
halfway between Max and Min and LogEC50 is the logarithm of
the EC50.
TZM-bl cell–based neutralization assay
The neutralizing capacity of antibodies purified from the plasma
of elite controllers was assessed using a modified TZM-bl assay
[4,28]. Briefly, TZM-bl cells (1610
4) were plated in 96-well plates,
cultured overnight, and neutralization assays were performed
using 10 time dilutions of antibody, starting at a concentration of
1 mg/mL. The diluted antibodies were mixed with 0.005 MOIs of
a fully replicating Tier 1A (SF162), Tier 2 (JRCSF), or SHIV-
SF162P3 virus, after which the antibodies and virus were
transferred onto TZM-bl cells. The controls included cells cultured
in the absence of virus, in the absence of antibodies (negative
control) or in the presence of 5 mg/mL of the b12 or b6
monoclonal antibodies (positive controls). After a 24-hour
incubation at 37uC, the cells were analyzed for luciferase
expression. The data were analyzed using non-linear regression
(curve fit) using Prism, and the percent neutralization obtained was
calculated after subtraction of the background as follows: 100 * (1-
[{RLU in the presence of both virus and antibody}/{RLU in the
absence of antibody}]). Any antibodies in which we observed
neutralization below 50% at 50 mg/mL were considered non-
neutralizing. The values reported in Figure 1C correspond to the
concentration of antibody necessary to achieve at least 50%
neutralization of both the Tier 1A and Tier 2 viruses.
Antibody-dependent cellular phagocytosis (ADCP)
Biotinylated antigen was incubated with 1 mm yellow-green
fluorescent neutravidin beads (Invitrogen) overnight. The beads
were then washed and resuspended at a final dilution of 1:100 in
PBS-BSA. Antibodies and 9610
5 antigen-labeled beads were
mixed in a round bottom 96-well plate, and the plate was
incubated for 2 hours. THP-1 cells (2610
4 cells) were then added
to each well in a final volume of 200 mL, and the plate was
incubated overnight under standard tissue culture conditions. The
next day, half the culture volume was removed and replaced with
100 mL of 4% paraformaldehyde before the plates were analyzed
on a BD LSR II equipped with an HTS plate reader. For analysis,
the samples were gated on live cells, and the proportion of THP-1
cells phagocytosing beads was determined. The data represents the
results of two separate experiments for which a phagocytic score
was calculated as follows: (% bead positive x MFI bead positive
[29]).
Rapid fluorometric antibody-dependent cellular
cytotoxicity (RFADCC)
The rapid fluorometric ADCC (RFADCC) assay was performed
as previously described [30]. Briefly, 1610
6 CEM.NKr cells (Dr.
Peter Cresswell through the AIDS Reagent Program, Division of
AIDS, NIAID, NIH) were pulsed with 6 mg of recombinant gp120
(YU-2) for 1 hour and then washed twice in cold R10. Uncoated
CEM.NKr cells were used as a negative control. Both the coated
and uncoated target cells were stained with 1.5 mM PKH26
(Sigma) and 100 nM 5-(and-6)-carboxyfluorescein diacetate,
succinimidyl ester (CFSE). After staining, the cells were resus-
pended at a concentration of 4610
5 cells/mL, and 2610
4 cells
were added to each well. Macaque antibodies were added
(500 mg/mL), and the plates were incubated for 20 minutes at
37uC and 5% CO2 to allow the binding of the antibodies to the
target cell. NK cells (2610
5) isolated from healthy rhesus
macaques using a customized CD3 Depletion Kit (Stem Cell
Technology) were added to each well (a final effector:target ratio
10:1). The plates were then incubated for 4 hours at 37uC, after
which the cells were fixed in 2% paraformaldehyde. ADCC
activity was determined using flow cytometry, on a minimum of
two separate donors and was based on the loss of CFSE on PKH
+
CEM.NKr cells. The data were analyzed using FlowJo software,
and the percentage of CFSE loss within the PKH
+ CEM.NKr
population was determined.
Surface Plasmon Resonance (SPR) assay
The ability of antibodies to bind to FcRs was determined using
surface plasmon resonance (Biacore). The CM5 sensor chip was
activated by injecting 25 mL of a mixture of an equal mixture of
NHS (0.1 M in water) and EDC (0.1 M in water) at 7 mL/min.
Next, 4.5 mg/mL of FcR diluted in 10 mM acetate buffer (pH 4.5)
Non-NAbs Do Not Protect from SHIV Challenge
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Unreacted sites were subsequently deactivated by injecting 25 mL
of 1 M ethanolamine (pH 8.5) at 7 mL/min. 125 ug/mL of
antibody were then run over the chip at a flow rate of 25 mL/min.
The affinity (RU), on-rate (Ka), off-rate (Kf) and overall binding
affinity (Kd) was compared among the different groups.
Antibody dependent complement deposition assay
The ability of antibodies to bind and activate the complement
was determined by the C3b deposition on gp120-pulsed target
cells. Briefly, 1610
6 CEM.NKr cells were pulsed with 6 mgo f
recombinant gp120 YU-2 or SF162 for 1 hour at room
temperature and then washed twice in cold R10. Uncoated
CEM.NKr cells were used as a negative control. Plasma from
healthy individuals was collected and used as a source of
complement for the assay. 25 ug of both the EC antibodies
selected for the in vivo challenge and the antibodies purified from
each 11 monkeys were added to 10
5 CEM.NKr cells in the
presence of plasma diluted 1:10 in veronal buffer supplemented
with 0.1% gelatin for 20 minutes at 37 degrees. Cells were washed
and stained with a FITC-conjugated C3b antibody for 15 minutes,
washed and fixed in 4% PFA. HIVIG was used a positive control
for this assay and heat inactivated plasma as well as antibodies
from healthy individuals were both used as negative controls. The
data are the results of two separate experiments.
Statistical analyses
All statistical analyses were performed using GrapPad Prism 5.0
software. Spearman rank correlation was used. Comparative
analyses of the viremia between both groups were performed using
an unpaired two-tailed t-test with 95% confidence intervals.
P-values were two-sided and not adjusted for multiple testing.
P-values less than 0.05 were considered statistically significant.
Results
Characterization of polyclonal ADCVI-inducing non-NAbs
for passive transfer experiments
While previous passive transfer experiments in which non-
neutralizing, ADCC-inducing antibodies were transferred failed to
protect macaques from infection [25], these experiments were
performed in neonatal rhesus macaques in which immature NK
cells with poor functionality or insufficient antibodies may have
contributed to an incapacity to form the immune complexes
necessary to stimulate the low affinity Fc receptors. Therefore, we
aimed to test whether a polyclonal pool of human non-neutralizing
antibodies could provide protection from infection. Previous
reports have shown that ADCC-inducing antibodies are signifi-
cantly enriched in subjects who spontaneously control HIV
infection in the absence of therapy, suggesting that these
polyclonal antibodies may contribute to viral containment in vivo
[12,13,17]. Since functional non-neutralizing antibodies from
normally progressing macaques have led to a reduction in viremia
Figure 1. Polyclonal antibodies from naturally infected donors have a wide range of non-neutralizing anti-viral activities. Antibodies
purified from the plasma of 15 different elite controllers (labeled EC-1 to EC15) were tested for their ability to bind to gp120 by ELISA, shown as the
inverse of EC50 (A), to mediate ADCVI, measured as a percent of inhibition of viral replication (B) and to neutralize HIV virus (JRCSF), measured as an
inverse of EC50 (C). The correlation plots show the relationship between gp120-specific antibody titers from elite controllers and ADCVI activity (D), or
virus neutralization (E) as well as the association between the neutralization and ADCVI activity of antibodies (F). The elite controller from which the
purified antibodies had the greatest innate immune recruiting properties in the absence of neutralization, EC10, was selected for passive transfer into
macaques and is highlighted in gray. A minimum of 2 separate experiments was assessed to select the EC antibodies that had the best activity.
doi:10.1371/journal.pone.0097229.g001
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[21–25], we performed a passive transfer of highly functional, non-
neutralizing antibodies from selected spontaneous controllers
exhibiting robust innate immune–recruiting activity to assess the
potential impact of polyclonal non-neutralizing antibodies on a
stringent SHIV-SF162P3 challenge. Thus, to identify a polyclonal
pool of antibodies with robust innate immune–recruiting activity
in the absence of neutralizing activity, we tested antibodies from
15 elite controllers. HIV-specific binding antibodies were observed
in all but one subject (Figure 1A). By contrast, the observed
ADCVI activity was heterogeneous, with robust functional activity
detected in only half of the tested subjects (Figure 1B). Neutralizing
antibody activity, measured in a TZM-bl assay, was very low in
nearly all subjects tested, except for EC-2 (Figure 1C). Finally,
ADCVI activity was only weakly correlated with the total gp120-
specific antibody titer (Figure 1D) and neutralizing antibody
activity showed no relationship with gp120-specific titers
(Figure 1E). Furthermore, ADCVI and neutralizing antibody
activity were unrelated to one another (Figure 1F). Based on these
data, the subject with the lowest neutralizing antibody activity and
the highest ADCVI activity (EC10; Figure 1A–C grey bars) was
selected for large-scale antibody collection. Bulk antibodies were
purified from a 100 mL plasma sample from EC10 using protein
A/G columns. In addition, antibodies from a pool of healthy,
HIV-negative individuals, were purified in parallel.
Purified IgG antibodies were reassessed for functional activity to
confirm the previously defined functional profile. As expected, the
purified antibodies from EC10 did not neutralize JRCSF, SF162
or SHIV-SF162P3 virus when measured using two distinct
methods: a TZM-bl assay (Figure 2A) as well as a primary CD4
T cell culture (Figure 2B) that captures the neutralizing activity of
antibodies targeting native envelope proteins, including gp41, for
which the TZM-bl assay has been previously shown to be
unreliable [3]. Following purification, the antibodies isolated from
EC10 continued to exhibit potent gp120-specific titers against YU-
2, SF162, gp140 specific antibody titer against SHIV-gp140-
SF162P3 (Figure 2C; EC10, EC50=3.4 mg/mL; b12,
EC50=0.4 mg/mL against YU-2) and potent gp41-specific
antibody titers (Figure 2C; EC50=1.45 mg/mL). Of note, p24-
specific antibodies were also detected in EC10 (data not shown).
Similarly, purified antibodies purified from the HIV-negative
donors continued to exhibit no gp120-reactivity or neutralizing
activity (Figure 2A-C). In addition, both the purified EC10
antibodies and the positive control b12 exhibited potent ADCVI
activity against the three tested viruses, whereas this activity was
absent from the antibodies purified from the HIV-negative
individuals (Figure 2D). Because antibodies are known to display
a wide variety of Fc-mediating antiviral activities, we also
evaluated their ability to mediate phagocytosis and to recruit
complement. Notably, we observed that the purified EC10
antibodies were able to induce potent gp120 (using YU-2 and
SF162 proteins)- and gp41- specific ADCP response (Figure 2E)
and activate complement deposition on YU-2 or SF162 pulsed
target cell lines (Figure 2F) whereas both activities were absent in
antibodies purified from the healthy individuals suggesting that
using different gp120 proteins, similar functionality were detected.
Thus, the isolated EC10 antibodies maintained their potent Fc-
mediated antiviral activity following large-scale purification.
ADCVI-inducing non-NAbs do not protect from infection
The purified antibodies from EC10 or HIV-negative controls
were administered intravenously at 50 mg/kg, approximating the
upper limit of HIV-specific monoclonal antibody passive transfer
and at roughly less than half of the dose of b12 required to achieve
sterilizing protection [8,31-33] and allowing for the delivery of
polyclonal antibodies from a single donor to 5 animals. One
animal received 25 mg/kg of the monoclonal antibody b12 that
was used as an internal control since the protection of b12 has
been previously reported to mediate protection from infection in
vivo [8]. All antibodies were delivered 1 day before a single
intermediate dose intrarectal challenge with SHIV-SF162P3 virus;
viral infection was monitored at days 1, 3, 7, 14, 28, 56 and 84
days post transfer, and samples were collected at the same time
points.
No difference was observed in the frequency of infected
macaques among animals that received antibodies from EC10
(four of five infected) or the antibodies from HIV-negative
individuals (three of five infected) (Figure 3A and B, respectively).
In contrast, the single, proof of concept, control animal that
received the b12 antibody remained uninfected with no detectable
viremia at month 3 post infection confirming that the challenge
virus can be blocked by a well-characterized monoclonal antibody
(Figure 3C).
Additionally, no differences were observed in peak viremia (EC
Ab-treated, mean 1.041e+007 copies/mL; HIV-NEG Ab-treated,
mean 8.831e+006 copies/mL) or viral set point (EC Ab-treated,
mean 144808 copies/mL; HIV-NEG Ab-treated, mean 1.693e+
006 copies/mL) following infection (Figure 3). Moreover, the area
under the curve (AUC) analysis of viral loads in the monkeys
receiving the EC Abs (median AUC=1.53e+007) compared to the
infected monkeys that received the HIV-NEG antibodies
(AUC=3.96e+007) were not statistically different (Figure 3C).
Thus, the passive transfer of polyclonal non-neutralizing antibod-
ies from an elite controller with potent innate immune-recruiting
activity was not able to protect rhesus macaques from or after
infection following a stringent rectal SHIV-SF162P3 challenge.
gp120-specific antibody titers and function do not
correlate with post-infection viral control
Previous data suggest that the passive transfer of non-
neutralizing, ADCC-inducing antibodies leads to post-infection
viral control [25,34]. To investigate parameters that may have
accounted for the lack of protection, we next evaluated the
dynamics of passively transferred polyclonal, non-neutralizing
antibodies. First, we measured gp120-specific antibody titers in the
plasma of all 7 infected monkeys. As expected, no gp120-specific
antibodies were detected in the plasma of macaques that received
antibodies from HIV-negative controls at early time points;
however, two of the control Ab–treated rhesus macaques mounted
gp120-specific antibody responses at Day 21 (Figure 4Ai). By
contrast, gp120-specific antibodies were detectable at Day 1 post-
transfer in animals receiving the elite controller antibodies, and
these antibody levels slowly decayed over the study period. Some
variation was observed in the plasma antibody levels as early as
Day 3, suggesting differential antibody-clearance among the
macaques (Figure 4Aii). Moreover, nearly all of the circulating
HIV-specific antibodies in the macaques were of the IgG1
subclass, suggesting that other antibody subclasses, which were
detectable prior to transfer, may have been cleared rapidly after
transfer (Figure 4B–E). Mucosal gp120-specific antibodies were
not detectable in the macaques at Day 7 post-transfer, suggesting
that either the antibodies penetrated the mucosa poorly, thereby
providing only limited protection at the site of inoculation, or that
the antibodies were cleared rapidly following transfer (data not
shown). Thus, in spite of the detection of high gp120-specific
antibody titers at early time points in all monkeys, no antibodies
were detected at mucosal barriers and only IgG1 antibodies
persisted in the blood.
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including gp120-specific ADCC, ADCP and complement depo-
sition as well as gp41-specific ADCC and ADCP activities. As
expected, no ADCC or ADCP activity was detected in the control
animals (Figure 4Fi and 4Gi, respectively). However, while both
gp120-specific ADCC and ADCP activities were observed in all
Figure 2. Antibodies purified from the elite controller selected for the in vivo study display a wide range of innate immune
recruiting properties. Large quantities of antibodies were purified from the plasma of EC10 and assessed for their neutralizing capacity in a TZM-bl
assay (A) and in a primary CD4 T cell assay (B). IgG HIV-binding titer against YU-2, SF162 gp120s, SHIVgp140 SF162p3 and gp41 was assessed (C)
along with ADCVI activity (D) against a tier 2 (JRCSF), a tier 1A (SF162) and the challenge virus (SHIV-SF162P3). Purified b12 and a pool of antibodies
purified from HIV-negative individuals were used as positive and negative controls, respectively. HIVIG was used as a positive control for testing
gp41-binding titer. Antibodies purified from the plasma of EC10 were also evaluated for their ability to induce ADCP against a tier 2(JRCSF), a tier 1A
(SF162) virus as well as against gp41 (E) and for their ability to induce complement activation as measured by C3b deposition on YU-2 or SF162 gp120
pulsed CEM cell line using HIVIG and a pool of antibodies purified from healthy individuals as positive and negative controls, respectively (F). A
minimum of 2 separate experiments was performed to confirm the innate immune recruiting properties of the antibodies from the selected EC.
doi:10.1371/journal.pone.0097229.g002
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antibodies (Figure 4Fii and 4Gii, respectively), these Fc mediated
functions correlated only weakly with viral control post infection.
Additionally, while complement activity was detected in the EC
Ab preparation prior to infusion, no complement deposition was
detected in any of the animals following antibody infusion
suggesting that antibody mediated complement deposition were
rapidly cleared following the passive transfer (data not shown).
Similarly, while gp41-specific ADCP activity was readily detect-
able prior to infusion, and gp41-specific Ab titers were clearly
detectable post-infection (Figure 5A), no gp41-specific ADCP
activity or antibody dependent NK cell activation was detectable
following passive transfer in the monkeys that received the EC
antibodies (Figure 5B and 5C, respectively). These data suggest the
potential preferential clearance of gp41-specific functional anti-
bodies and all complement activating antibodies following passive
transfer.
Overall, these data show that the passive transfer of a polyclonal
pool of non-neutralizing antibodies with potent ADCVI activity
did not protect from infection following a stringent SHIV-
SF162P3 challenge. Antibody transfer dynamics revealed limited
delivery of antibodies to the rectal mucosa and the selective loss of
antibody-subpopulations following passive transfer potentially
limiting the functional properties of the transferred polyclonal
antibodies. These data raise the possibility that either non-
neutralizing antibodies may not provide protection from or after
infection or that other Fc mediated antiviral functions, alone or in
combination, may have a greater impact on viral control. Thus,
larger passive transfer experiments in which higher concentrations
of antibodies are infused, or delivered specifically to the sites of
challenge, may help definitively prove the protective role of non-
neutralizing functional antibodies.
Discussion
Recent results from the correlates analysis of the RV144 vaccine
trial [35] pointed to a protective role of non-neutralizing
antibodies in the control of HIV infection. Specifically, in the
absence of vaccine-elicited IgA responses, several features of the
antibody functional profile, including ADCC activity, were
correlated with a reduced risk of infection. However, over the
past decade, attempts to examine the protective role of non-
neutralizing antibodies in the non-human primate model
[21,22,24] have failed to mechanistically link antibodies that lack
neutralizing activity to protection from infection. However, these
negative results may be the result of several inherent difficulties
associated with study design using non-neutralizing antibodies,
including 1) the use of single monoclonal antibodies [31,32,36]
[37] or pooled monoclonals [33,38–42] [43], which target a
limited number of epitopes and therefore induce poor immune
complex formation, and 2) the use of NHP polyclonal sera with
ADCC activity, which has not been associated with the durable
antiviral activity observed in long-term non-progressors. To
circumvent these problems, we performed a passive transfer
experiment in rhesus macaques using polyclonal, ADCC-inducing
antibodies isolated from an elite controller that exhibited non-
neutralizing control of infection. No sterilizing protection from
infection was observed following a rectal SHIV-SF162P3 chal-
lenge. Subsequent ex vivo analysis of transferred antibodies
demonstrated unexpected antibody clearance post-transfer result-
ing in minimal antibody delivery to the rectal mucosa, selective
loss of all non-IgG1 antibody subclasses in the blood, selective
depletion of gp41-specific ADCP antibodies, and elimination of all
complement activating antibodies. Such alterations in antibody
subpopulations could profoundly alter in vivo functionality and
therefore protective activity. However, despite this alteration,
weak, but insignificant associations, were observed between
gp120-specific titers and Fc-receptor binding characteristics with
post-infection viral control (data not shown).
While the passive transfer of broadly neutralizing antibodies has
been successful in mediating sterilizing protection in rhesus
macaques, vaccines that elicit these responses have proven elusive.
More recently, vaccine strategies that induce non-neutralizing
functional antibodies have shown only limited success in prevent-
ing infection [21–24]. However, unlike neutralizing antibodies that
simply block a limited number of viral epitopes on the surface of a
virus, non-neutralizing antibodies must form avid immune
complexes that are able to recruit the low-affinity receptors or
innate immune proteins necessary for their function. Therefore, it
is not surprising that the transfer of a polyclonal pool of non-
neutralizing antibodies with the capacity to form these immune
complexes may be required for protection. However, while the
passive transfer of polyclonal sera, such as IVIG, is usually 8 times
higher than the dose selected here (400 mg/kg), the bioactive dose
of sialated anti-inflammatory antibodies or pathogen-specific
antibodies are only a minute fraction of the total transferred
antibodies [44]. Notably, it has been previously shown that HIV-
Figure 3. Kinetics of plasma viremia following SHIV-SF162P3 challenge. 50 mg/kg of antibodies purified from the selected elite controller
(A) or from HIV-negative individuals (B) were passively transferred intravenously one day prior to the challenge with SHIV-SF162P3 in 5 rhesus
macaques each. The plasma viremia was measured 14 days before and 1, 3, 7, 14, 21, 28, 56 and 84 days after antibody transfer. No viremia was
detected in the animal that received 25 mg/kg of the b12 monoclonal antibodies used as a positive control. The area under the curve (AUC) of viral
loads was measured in the 4 infected monkeys that received the EC antibodies and the 3 infected monkeys that received HIV-NEG antibodies (C). An
unpaired two-tailed t-test with 95% confidence intervals was used to compare the AUC between both groups.
doi:10.1371/journal.pone.0097229.g003
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antibody pool [44], suggesting that the total fraction of HIV-
specific antibody transferred in this study may have only
approximated 1 mg/kg, at roughly less than half of the dose of
b12 required to achieve sterilizing protection, potentially account-
ing for reduced protective efficacy. While these levels may be
sufficient to block infection by some of the newer potent broadly
neutralizing antibodies [45], significantly higher levels are likely
Figure 4. Kinetics of gp120-specific antibody titers and innate immune recruiting properties of antibodies following SHIV-SF162P3
challenge. ELISA was used to test the level of gp120-specific antibodies in the plasma of infected rhesus macaques (A) that received purified
antibodies from either the pool of HIV-negative individuals (i) or the elite controller (ii). Optical Density (OD) values are reported. The level of gp120
specific antibody subclass over time was measured by Luminex in the plasma of the 4 infected monkeys that received the EC antibodies as well as in
one monkey that received the HIV-NEG antibodies and is reported as mean fluorescence intensity (B–E). Antibodies were purified from the rhesus
monkeys that received the EC antibodies (i) or the HIV-NEG antibodies (ii) and tested for their ability to recruit NK cells to mediate ADCC (F) or to
recruit monocytes to mediate phagocytosis (G) 2 weeks prior the antibody transfer and at day 1, 3, 7, 14, 21 and 28 post antibody transfer. NK cells
isolated from 2 separate donors were used to assess ADCC and 2 separate experiments were performed to measure the phagocytic activity.
doi:10.1371/journal.pone.0097229.g004
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incoming virus. Recently, passive immunization in macaques with
a polyclonal pool of anti SHIV IgG conclusively showed the
critical nature of the transferred antibody dose [46]. Of note, the
study demonstrated that passive transfer of 25 mg/kg of antibodies
increased acquisition in a complement dependent manner, while
partial protection was observed at 625 mg/kg, where HIV-specific
antibodies still only constituted a transfer of 12.5 mg/kg. This data
offers compelling evidence that protection can be achieved with
non-neutralizing antibodies, and that perhaps the transfer or
induction of similar doses of highly functional antibodies may offer
even greater protection from infection. Thus future passive
transfer with higher levels of elite controller antibodies, at ten-
fold higher levels, may be required to achieve protection from
infection, but may show enhanced protection from infection in the
absence of neutralization.
Because most HIV transmissions occur across mucosal surfaces,
the development of a successful, protective vaccine will likely
require the presence of HIV-specific antibodies that harbor potent
functional properties at the mucosal barrier. In the current study,
transferred EC antibodies were not detected in the rectal mucosa
at Day 7, potentially contributing to the lack of observed
protection. Thus, it is plausible that either only low levels of the
systemically administered antibodies reached the rectal mucosa
and/or that the antibodies that reached the mucosa were cleared
more rapidly in tissues compared to the blood. Therefore, future
non-neutralizing antibody transfer studies may aim to deliver
antibodies directly at the site of inoculation to define the critical
humoral parameters involved in antiviral control.
While no protective activity of the passively transferred
antibodies was detected, ancillary analyzes revealed that gp120
specific, but not gp41 specific, ADCC and ADCP were detectable
in all 4 infected monkeys that received the EC Abs following
infection, 2 functions that have been previously shown to control
HIV replication in both humans and rhesus macaques
[7,12,17,47]. Of note, a blip in the ADCP activity was observed
in one of the monkeys that received the HIV-negative antibodies
following challenge, which was repeatedly shown to be non-HIV-
specific. Because the HIV envelope protein is highly glycosylated,
it is plausible that in this animal, natural antibodies may have
emerged following infection, mimicking some of the autoimmune-
like antibody responses documented in subjects that elicit broadly
neutralizing antibody response against HIV [48]. Additionally,
while Fc mediated antiviral properties of antibodies are tightly
linked to their ability to bind to Fc-receptors and that we observed
a weak but not statistically significant correlation between Fc-
receptor binding and post infection viral control (data not shown),
future efforts aimed at selecting sera with potent Fc-receptor
binding, as a surrogate of robust Fc mediated activity, may help
conclusively define the role for non-neutralizing antibodies in
protection from infection.
Thus overall, no sterilizing protection was observed following
the intravenous passive transfer of a low dose of non-neutralizing
ADCVI-mediating antibodies using a rectal SHIV-SF162P3
challenge. While previous studies have pointed toward a crucial
role for ADCC activity in viral control in both humans and rhesus
monkeys, future experiments using an increased concentration of
functional antibodies, both peripherally and at the site of
challenge, may contribute to lowered viremia following infection.
Figure 5. Kinetics of gp41-specific antibody titers and contribution of Fc mediated gp41 specific antibody responses following
SHIV-SF162P3 challenge. The level of gp41 specific antibody subclass over time was measured by Luminex in the plasma of the 4 infected
monkeys that received the EC antibodies as well as in one monkey that received the HIV-NEG antibodies and is reported as mean fluorescence
intensity (A). Antibodies were purified from the rhesus monkeys that received the EC antibodies or the HIV-NEG antibodies and tested for their ability
to recruit monocytes to mediate phagocytosis (B) or to activate NK cell measured as a release of CD107a, MIP1b and IFNc (C) 2 weeks prior the
antibody transfer and at day 1, 3, 7, 14, 21 and 28 post antibody transfer.
doi:10.1371/journal.pone.0097229.g005
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the design of future animals studies aimed at conclusively defining
the antiviral effect of polyclonal non-neutralizing HIV-specific
antibodies.
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